The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: Guidance for Today and the Path ForwardPremiere Date: Tuesday, December 1, 2020
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, December 1, 2021
Note: Credit Is No Longer Available
|Hossein Borghaei, DO, MS (Moderator)
Chief, Division of Thoracic Medical Oncology
Professor, Department of Hematology/Oncology
Gloria and Edmund M. Dunn Chair in Thoracic Oncology
Fox Chase Cancer Center
|Enriqueta Felip, MD, PhD
Section in Chief, Medical Oncology Department
Head, Thoracic and Head and Neck Oncology Unit
Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology
Associate Professor of Medicine (UCC)
|David E. Gerber, MD
Professor of Internal Medicine and Population & Data Sciences
University of Texas Southwestern Medical Center
Associate Director of Clinical Research
Co-Leader of the Experimental Therapeutics Scientific Program
Harold C. Simmons Comprehensive Cancer Center at UT Southwestern
The discovery of molecular alterations that drive tumor initiation and progression has revolutionized the treatment strategy for non-small cell lung cancer (NSCLC) by matching targeted therapies to a specific mutation, leading to significantly improved therapeutic efficacy. However, despite the initial effectiveness of targeted therapy for NSCLC, most patients ultimately develop acquired resistance with subsequent disease progression, making it imperative for clinicians to receive up-to-date education on evaluating new therapeutic options to improve outcomes and better tailor treatment strategies.
In this CME Outfitters Live and OnDemand, integrations of animated 3-D models will provide visual representation of the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC to complement expert faculty insights and evidence supporting testing strategies to identify predictive biomarkers, emerging treatment options for advanced or metastatic NSCLC, and best practices for managing patients with lung cancer in the face of COVID-19 and beyond.
At the end of this CE activity, participants should be able to:
- Apply molecular testing to identify predictive biomarkers for targeted therapy in advanced NSCLC.
- Evaluate the rationale for emerging therapies in advanced or metastatic NSCLC
- Employ best practices to manage lung cancer during the COVID-19 pandemic.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Summarize how molecular testing can identify predictive biomarkers for targeted therapy in advanced NSCLC.
- Evaluate the rationale for emerging therapies in advanced or metastatic NSCLC.
- Describe best practices to manage lung cancer during the COVID-19 pandemic.
Supported by an educational grant from Daiichi Sankyo, Inc.
Hematology/oncology specialists, surgeons, pathologists, nurse practitioners, PAs, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC: Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Borghaei reports he receives research support from Bristol-Myers Squibb Company/Eli Lilly and Company and Merck & Co./Celgene Corporation. He is on the advisory committee for AbbVie Inc.; Amgen Inc.; AstraZeneca; Axiom Healthcare Services; BioNTech; Boehringer Ingelheim; Bristol-Myers Squibb Company; Cantargia AB; Celgene Corporation; Daiichi Sankyo, Inc.; Eli Lilly and Company; EMD Serono, Inc.; Genentech, Inc.; Genmab; GLG; HUYA Bioscience International; Merck & Co.; Novartis; Pfizer Inc.; PharmaMar; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Amgen; AstraZeneca; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; EMD Serono, Inc.; and PharmaMar. He receives other financial or material support from Data and Safety Monitoring Board: Incyte; Takeda Pharmaceuticals U.S.A., Inc. and University of Pennsylvania. He is on the scientific advisory board for Rgenix (stock options) and Sonnet BioTherapeutics, Inc. (stock options).
Dr. Felip reports she receives research funding from Fundaci�n Merck Salud and a grant for Oncology Innovation (GOI) EMD Serono. She serves in a advisory role or speakers bureau for for AbbVie Inc.; Amgen Inc.; Astra Zeneca, Bayer, Blueprint Medicines Corporation; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; F. Hoffmann-La Roche; GlaxoSmithKline; Janssen Global Services; Merck KGaA; Merck Sharp & Dohme Corp.; Novartis; Pfizer Inc.: Puma Biotechnology, Inc.; Sanofi Genzyme, Springer; and Takeda Pharmaceutical Company. She recieves other financial or material support from Grifols (independent board member).
Dr. Geber reports he receives research support from AstraZeneca; BerGenBio; Bristol-Myers Squibb Company; and Karyopharm. He is a consultant for Bristol-Myers Squibb Company; Catalyst Pharmaceuticals, Inc.; G1 Therapeutics, Inc.; Karyopharm; and Samsung Bioepis. He is a stock shareholder (directly purchased) in Gilead Sciences, Inc.
Poshala Tish Aluwihare, PhD (planning committee) has no disclosures to report.
Howard Bliwise, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).